In one paragraphArticle in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Takahiro HobaraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0009-0001-2900-182X Masahiro AndoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-6187-9042 Yujiro HiguchiDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan. higuchi0302@m2.kufm.kagoshima-u.ac.jp.ORCID http://orcid.org/0000-0002-5579-4384 Jun-Hui YuanDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-3808-7813 Akiko YoshimuraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-1768-3181 Naoki FukushimaDepartment of Pediatrics, Nakatsu Municipal Hospital, Oita, Japan.
Chikashi YanoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0009-0002-1468-3415 Fumikazu KojimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0009-0004-7867-2285 Kento KodamaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.
Yu HiramatsuDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-1217-0870 Satoshi NozumaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-4909-7769 Tomonori NakamuraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-4618-9369 Yusuke SakiyamaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0003-0691-1705 Akihiro HashiguchiDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0002-6114-998X Hiroshi TakashimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.ORCID http://orcid.org/0000-0003-0989-6141 Funding
Japan Agency for Medical Research and Development 201442014AJapan Agency for Medical Research and Development 201442071AJapan Agency for Medical Research and Development JP14ek0109065Japan Agency for Medical Research and Development JP20ek010949JSPS KAKENHI JP18H02742JSPS KAKENHI JP20K16604JSPS KAKENHI JP21H02842JSPS KAKENHI JP21K15702JSPS KAKENHI JP22K07495JSPS KAKENHI JP22K07519JSPS KAKENHI JP22K15713JSPS KAKENHI JP23K06931JSPS KAKENHI JP23K06966JSPS KAKENHI JP24K18708Research Committee for Ataxic Disease 2016100002B
6 · The paper itselfAbstract
backgroundGiant axonal neuropathy 1 (GAN) is a rare neurodegenerative disorder with autosomal recessive inheritance and significant phenotypic heterogeneity, ranging from milder presentations resembling Charcot-Marie-Tooth disease (CMT) to classical presentations involving central and peripheral nervous systems. We investigated the genetic and clinical spectrum of GAN in Japanese patients with inherited peripheral neuropathies (IPNs).
methodsWe conducted genetic screening of 3315 Japanese patients diagnosed with IPNs between 2007 and 2023 using targeted next-generation or whole-exome sequencing. Variant pathogenicity, clinical features, and neurophysiological and neuroimaging findings were reviewed.
resultsWe identified seven biallelic GAN variants in five patients from four unrelated families, including one homozygous and three compound heterozygous genotypes. Two novel pathogenic variants were identified: c.922G > T (p.Glu308*) and c.456dup (p.Ala153Cysfs*27). Two families exhibited the classical phenotype, whereas the other two exhibited a CMT-like phenotype. Mean onset age was 4.4 years (range 1.5-8), and gait disturbance was the initial symptom. The most common findings included distal weakness (n = 5), sensory impairment (n = 4), scoliosis (n = 3), autonomic dysfunction (n = 2). Neurophysiologically, all patients had sensorimotor axonal polyneuropathy. One patient with mild phenotype maintained a CMT-like state without systemic involvement until the age of 43 years and was still alive at 72, representing the longest documented survival in GAN.
conclusionThis study expands the genetic and phenotypic spectrum of GAN by identifying novel variants and a long-term survivor. These findings underscore the importance of systematic genetic screening for GAN in pediatric-onset CMT, even in the absence of classical features.
Indexed as
Charcot-Marie-Tooth DiseaseGiant Axonal NeuropathyAdolescentAdultChildChild, PreschoolEast Asian PeopleFemaleGenetic TestingHumansInfantJapanMaleMiddle AgedPedigreePhenotypeCharcot–Marie–Tooth diseaseGiant axonal neuropathyGigaxoninInherited peripheral neuropathyNext-generation sequencingPhenotypic heterogeneity
Identifiers
PMID40668264
PMCPMC12267338
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390